Top-Rated StocksTop-RatedNASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free APLS Stock Alerts $56.26 -0.48 (-0.85%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$55.97▼$57.4850-Day Range$56.26▼$72.4752-Week Range$19.83▼$94.75Volume975,358 shsAverage Volume1.63 million shsMarket Capitalization$6.78 billionP/E RatioN/ADividend YieldN/APrice Target$77.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Apellis Pharmaceuticals alerts: Email Address Apellis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside38.5% Upside$77.93 Price TargetShort InterestBearish8.34% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.56Based on 12 Articles This WeekInsider TradingSelling Shares$20.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to $1.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.61 out of 5 starsMedical Sector92nd out of 947 stocksPharmaceutical Preparations Industry37th out of 435 stocks 4.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.93, Apellis Pharmaceuticals has a forecasted upside of 38.5% from its current price of $56.26.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.34% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently decreased by 2.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 2.5 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Apellis Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 7 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows21 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 62% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,956,583.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions90.43% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.36) to $1.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -12.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -12.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 34.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Apellis Pharmaceuticals Stock (NASDAQ:APLS)Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More APLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLS Stock News HeadlinesMarch 16, 2024 | insidertrades.comNur Nicholson Sells 11,220 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockMarch 6, 2024 | marketbeat.comBeam Therapeutics Bolts Higher on Gene Therapy Licensing Payments (APLS)Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in placeMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 16, 2024 | finance.yahoo.comAPLS Mar 2024 56.000 putMarch 16, 2024 | finance.yahoo.comAPLS Mar 2024 59.000 callMarch 16, 2024 | finance.yahoo.comAPLS Mar 2024 50.000 putMarch 15, 2024 | benzinga.comPeering Into Apellis Pharmaceuticals's Recent Short InterestMarch 14, 2024 | finance.yahoo.comApellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 SharesMarch 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 11, 2024 | globenewswire.comApellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina AdvisorMarch 10, 2024 | finance.yahoo.comAPLS Mar 2024 69.000 callMarch 10, 2024 | finance.yahoo.comAPLS Mar 2024 58.000 putMarch 6, 2024 | globenewswire.comApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | finance.yahoo.comAPLS Mar 2024 62.000 putMarch 5, 2024 | uk.finance.yahoo.comAPLS Mar 2024 90.000 callFebruary 29, 2024 | seekingalpha.comApellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comDeep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)February 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Strong Syfovre Performance and Expanding Market OpportunitiesFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Expanding Market PotentialFebruary 27, 2024 | finanznachrichten.deApellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comStrong Syfovre Sales Drive Buy Recommendation for Apellis Pharmaceuticals with Revised $85 Price TargetFebruary 27, 2024 | seekingalpha.comApellis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | globenewswire.comApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | msn.comApellis Pharmaceuticals Q4 2023 Earnings PreviewFebruary 26, 2024 | globenewswire.comApellis Pharmaceuticals to Present at Upcoming Investor ConferencesFebruary 24, 2024 | msn.comApellis Pharmaceuticals (APLS) Price Target Increased by 6.05% to 81.53February 24, 2024 | finance.yahoo.comAPLS Mar 2024 66.000 callSee More Headlines Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees702Year Founded2009Price Target and Rating Average Stock Price Target$77.93 High Stock Price Target$106.00 Low Stock Price Target$54.00 Potential Upside/Downside+37.5%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($4.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-528,630,000.00 Net Margins-133.34% Pretax Margin-132.76% Return on Equity-178.60% Return on Assets-60.41% Debt Debt-to-Equity Ratio0.48 Current Ratio3.10 Quick Ratio2.50 Sales & Book Value Annual Sales$396.59 million Price / Sales17.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book34.57Miscellaneous Outstanding Shares120,582,000Free Float111,538,000Market Cap$6.84 billion OptionableOptionable Beta0.90 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Cedric Francois M.D. (Age 52)Ph.D., Co-Founder, President, CEO & Director Comp: $1.2MDr. Pascal Deschatelets Ph.D. (Age 54)Co-Founder & Chief Scientific Officer Comp: $688.05kMr. Alec Machiels J.D. (Age 51)MBA, Co-Founder & Director Comp: $72.5kMr. Timothy E. Sullivan (Age 53)CFO & Treasurer Comp: $716.41kMr. Adam J. Townsend (Age 46)Chief Operating Officer Comp: $701.61kMr. David O. Watson Esq. (Age 51)J.D., General Counsel Comp: $675.35kMr. James G. Chopas CPA (Age 57)VP, Corporate Controller & Chief Accounting Officer Ms. Meredith KayaSenior Vice President, Investor Relations & Strategic FinanceMs. Karen Lewis (Age 51)Chief People Officer Prof. Peter Hillmen M.D.Ph.D., Head of Hematology Engagement & Member of PNH Scientific Advisory BoardMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZViking TherapeuticsNASDAQ:VKTXCytokineticsNASDAQ:CYTKCerevel TherapeuticsNASDAQ:CEREElanco Animal HealthNYSE:ELANView All CompetitorsInsiders & InstitutionsJames George ChopasSold 184 sharesTotal: $10,388.64 ($56.46/share)Nur NicholsonSold 11,220 sharesTotal: $645,823.20 ($57.56/share)Vanguard Group Inc.Bought 85,701 shares on 3/11/2024Ownership: 7.925%Cedric FrancoisSold 250,000 sharesTotal: $16.03 M ($64.11/share)Goldman Sachs Group Inc.Sold 41,210 shares on 3/1/2024Ownership: 0.258%View All Insider TransactionsView All Institutional Transactions APLS Stock Analysis - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price target for 2024? 15 Wall Street research analysts have issued 1 year target prices for Apellis Pharmaceuticals' shares. Their APLS share price targets range from $54.00 to $106.00. On average, they anticipate the company's stock price to reach $77.93 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2024? Apellis Pharmaceuticals' stock was trading at $59.86 at the start of the year. Since then, APLS shares have decreased by 6.0% and is now trading at $56.26. View the best growth stocks for 2024 here. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our APLS earnings forecast. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.73) earnings per share for the quarter, meeting the consensus estimate of ($0.73). The firm earned $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative trailing twelve-month return on equity of 178.60%. The firm's revenue was up 545.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.50) EPS. What ETFs hold Apellis Pharmaceuticals' stock? ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI). What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.06%), Vanguard Group Inc. (7.92%), Jennison Associates LLC (2.76%), Octagon Capital Advisors LP (2.37%), Price T Rowe Associates Inc. MD (2.08%) and Price T Rowe Associates Inc. MD (2.08%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.Read More This page (NASDAQ:APLS) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.